WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Samuel A. Minaker, MD, discusses the 0.19 mg fluocinolone acetonide implant for diabetic macular edema.
According to Minaker, 70% of patients in the PALADIN real-world safety study did not require any intervention after treatment, and the need for surgery was rare. The study also looked at the variability of central subfield thickness and its effect on vision outcomes.
“When we looked at the need for treatment in these quartiles, these patients’ visual gains were not driven by additional supplemental treatment